---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-042937"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2022-02-15T23:59:59+00:00"
generated_at: "2026-06-27T07:54:59.079700+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neoleukin CFO Robert Ho resigns effective March 1, 2022

## Summary
- CFO and Corporate Secretary Robert Ho notified intent to resign to pursue another opportunity.
- Resignation effective March 1, 2022; no successor named in the filing.
- Company provided no details on interim or permanent replacement plans.

## SEC filing metadata
- accession: 0001193125-22-042937
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2022-02-15T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000119312522042937/0001193125-22-042937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000119312522042937/d282321d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-042937
- JSON: https://secwatch.observer/filing/0001193125-22-042937.json
- Plain text: https://secwatch.observer/filing/0001193125-22-042937.txt

## Key facts
- Executive change
  Robert Ho departed as Chief Financial Officer and Corporate Secretary at Neurogene Inc..
  - Action: resign
  - Role: Chief Financial Officer and Corporate Secretary
  source text: On February 14, 2022, Neoleukin Therapeutics, Inc. (the “Company”) received notice from Robert Ho of his intention to resign as the Company’s Chief Financial Officer and Corporate Secretary to pursue another opportunity, effective March 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000119312522042937/0001193125-22-042937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.